within Pharmacolibrary.Drugs.ATC.C;

model C10AX11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0060999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0043,
    k12             = 4.1,
    k21             = 4.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AX11</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein B-100 synthesis, used for the treatment of homozygous familial hypercholesterolemia to reduce LDL cholesterol. It was approved by the FDA but is not currently marketed in many regions, including the US, due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with homozygous familial hypercholesterolemia after subcutaneous administration.</p><h4>References</h4><ol><li><p>Hair, P, et al., &amp; McKeage, K (2013). Mipomersen sodium: first global approval. <i>Drugs</i> 73(5) 487–493. DOI:<a href=&quot;https://doi.org/10.1007/s40265-013-0042-2&quot;>10.1007/s40265-013-0042-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23564617/&quot;>https://pubmed.ncbi.nlm.nih.gov/23564617</a></p></li><li><p>Li, Z, et al., &amp; von Moltke, LL (2014). Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. <i>International journal of clinical pharmacology and therapeutics</i> 52(4) 314–320. DOI:<a href=&quot;https://doi.org/10.5414/CP201975&quot;>10.5414/CP201975</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24548981/&quot;>https://pubmed.ncbi.nlm.nih.gov/24548981</a></p></li><li><p>Geary, RS, et al., &amp; Crooke, ST (2015). Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. <i>Clinical pharmacokinetics</i> 54(2) 133–146. DOI:<a href=&quot;https://doi.org/10.1007/s40262-014-0224-4&quot;>10.1007/s40262-014-0224-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25559341/&quot;>https://pubmed.ncbi.nlm.nih.gov/25559341</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AX11;
